|1.||Parashar, Umesh D: 7 articles (12/2015 - 02/2010)|
|2.||Tate, Jacqueline E: 6 articles (12/2015 - 07/2013)|
|3.||Payne, Daniel C: 5 articles (12/2015 - 11/2012)|
|4.||Vesikari, Timo: 5 articles (06/2015 - 10/2004)|
|5.||Bowen, Michael D: 4 articles (12/2015 - 11/2012)|
|6.||Yen, Catherine: 4 articles (12/2015 - 03/2014)|
|7.||Han, Htay Htay: 4 articles (11/2013 - 04/2009)|
|8.||Nakagomi, Osamu: 4 articles (11/2013 - 10/2007)|
|9.||Suryakiran, P V: 4 articles (04/2013 - 02/2009)|
|10.||Mijatovic-Rustempasic, Slavica: 3 articles (12/2015 - 07/2013)|
09/01/2010 - "Results of phase III studies in Europe, Latin America, and Asia have shown that Rotarix offers sustained high protection against severe rotavirus gastroenteritis during the first 2 years of life, when disease burden is highest, with broad protection demonstrated against each of the 5 main rotavirus types that circulate globally (G1, G2, G3, G4, and G9). "
10/09/2009 - "This study evaluates the safety and efficacy against severe rotavirus gastroenteritis of the oral live attenuated human rotavirus vaccine RIX4414 (Rotarix) during the first 2 years of life in Asian infants from high-income countries. "
08/01/2009 - "The protective efficacy against severe rotavirus gastroenteritis afforded by Rotarix is consistently better against strains that share with RIX4414 both G and P serotypes (i.e., G1P), or only P serotype (i.e., G3P, G4P and G9P). "
12/01/2009 - "It provided 85-96% protection against severe rotavirus gastroenteritis caused by G1 and non-G1 serotypes in Latin American and European clinical trials; and of public health importance, Rotarix reduced hospitalizations of all-cause gastroenteritis by 40 and 75%, respectively. "
11/24/2007 - "We aimed to assess the efficacy of the oral live attenuated human rotavirus vaccine Rotarix (RIX4414) for prevention of rotavirus gastroenteritis in European infants during their first 2 years of life. "
01/01/2008 - "A two-dose vaccine against rotavirus infection (RIX4414; Rotarix, GlaxoSmithKline), has been shown to be highly effective against severe RVGE. "
07/16/2009 - "This study estimated the cost-effectiveness of infant rotavirus vaccination with Rotarix in the UK, taking into account community rotavirus infections that do not present to the healthcare system. "
03/01/2015 - "We report for the first time Rotarix vaccine-acquired rotavirus infections with viremia in 2 infants vaccinated before being diagnosed with severe combined immune deficiency. "
01/01/2008 - "A Markov model simulated RVGE events and the associated outcomes and costs relating to general vaccination of infants against rotavirus infection using RIX4414 (Rotarix) in a birth cohort of children aged up to 5 years in France with a combined adjustment for age distribution with the seasonality of the infection. "
10/21/2010 - "Comment on the contribution by Weycker et al., "Cost of routine immunization of young children against rotavirus infection with Rotarix ® versus RotaTeq ®"."
10/01/2015 - "Our model predicts that the introduction of Rotarix might result in major strain replacement in regions such as North America where the prevalence of G1P is relatively high, due to higher efficacy of Rotarix against infection caused by G1P, while regions with lower prevalence of G1P, such as South America, are not susceptible to major strain replacement. "
11/01/2013 - "There was no immunological or clinical evidence of PCV1 infection in infants who had received Rotarix in clinical trials. "
10/01/2015 - "We developed a two-strain epidemiological model of rotavirus transmission, and used it to examine the effects of a monovalent vaccine (Rotarix) on the qualitative behaviors of infection levels in a population. "
08/01/2013 - "There is substantial evidence for broad cross-reactive immunity and heterotypic protection among human rotavirus strains in children with natural infection or with monovalent Rotarix vaccination. "
01/17/2011 - "Passaging of the supernatant indicated productive infection in PCV1-infected PS cells, but not in HEK293 and Vero cells or in any cell line incubated with Rotarix. "
07/01/2015 - "Some studies suggest that Rotarix(TM) may have a temporal association with a risk of intussusception (IS). "
01/01/2006 - "A large scale safety trial, conducted in Latin America plus Finland, indicated no increased risk of intussusception among recipients of Rotarix compared with placebo. "
06/17/2014 - "Rotarix(®) is estimated to cause one additional intussusception admission in every 18,551 vaccinated English infants (5th and 95th percentiles, 6728-93,952), equivalent to 35 (7-98) additional intussusception admissions each year. "
11/01/2013 - "When the first dose is administered between 6 and 14 weeks of age and the last dose by 24 weeks of age, Rotarix carries a small risk of intussusception within the week of vaccination. "
08/01/2009 - "The Rotarix vaccine is safe regarding intussusception if its first dose is administered between 6 and 12 weeks of age and the last dose by 24 weeks of age with a minimum interval of 4 weeks between the two doses. "
09/01/2015 - "Childhood diarrhea deaths and hospital admissions have declined since the introduction of the monovalent (G1P) vaccine (Rotarix(®) [RV1]) in the National Immunization Program in Brazil in 2006. "
02/01/2010 - "Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P strains in Brazil."
01/01/2015 - "Rotarix substantially reduced the prevalence of RVAGE, with a 67 % reduction of severe RVAGE hospitalizations, and over 50 % reduction of diarrhea with severe dehydration. "
07/01/2013 - "Genotyping of human rotaviruses was performed on 299 (40.1%) rotavirus-positive samples obtained from 745 children with acute diarrhea in three provinces in South Korea between March 2008 and February 2010, approximately 2 years following the introduction of the RotaTeq (September 2007) and Rotarix (July 2008). "
03/04/2009 - "A routine rotavirus immunization program would prevent 146,470 (Rotarix) or 149,937 (RotaTeq) cases of rotavirus diarrhea per year, and would prevent 21,106 (Rotarix) and 23,057 (RotaTeq) serious cases (hospitalizations, emergency department visits, and death). "
|7.||Chickenpox Vaccine (Vaccine, Varicella)
|9.||DNA (Deoxyribonucleic Acid)